Previous 10 | Next 10 |
Start Time: 16:30 End Time: 16:47 Celcuity Inc. (CELC) Q2 2020 Earnings Conference Call August 10, 2020, 16:30 PM ET Company Participants Brian Sullivan - Co-Founder and CEO Vicky Hahne - CFO Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright William F...
- Presented data for first CELsignia Pathway Activity Test for ovarian cancer at AACR Annual Meeting - - Expect to announce new clinical trial collaborations with pharmaceutical companies and trial sponsors by the end of 2020 - - Cash burn rate steady - - Cash and Cash Equiva...
MINNEAPOLIS, MN / ACCESSWIRE / July 24, 2020 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced that it will release its financial re...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Webcast on July 13, 2020 at 1 pm (ET) MINNEAPOLIS, MN / ACCESSWIRE / July 1, 2020 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, ann...
Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: patient sub-group may benefit from HER2 therapy or c-Met and pan-HER combination therapy Celcuity's first test for ovarian cancer patients MINNEAPOLIS, MN / ACCESSWIRE / June 22, 2020 / Celcu...
Celcuity (NASDAQ: CELC ): Q1 Non-GAAP EPS of -$0.17 in-line; GAAP EPS of -$0.22 misses by $0.02 . More news on: Celcuity Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Significant progress made in development of new, highly precise diagnostics using proprietary CELsignia platform Expect to announce new clinical trial collaborations with pharmaceutical companies and trial sponsors by the end of 2020 Expects to complete development of a CELsignia R...
MINNEAPOLIS, MN / ACCESSWIRE / April 23, 2020 / Celcuity Inc. (NASDAQ:CELC), a functional cellular analysis company that is developing companion diagnostic tests designed to expand the eligible patient populations for targeted therapies, announced that it will release its financial results f...
Gainers: Camber Energy (NYSEMKT: CEI ) +61% . More news on: Camber Energy, Inc., Cancer Genetics, Inc., Micron Solutions, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. ...
2024-05-30 16:00:09 ET Bradley Canino from Stifel Nicolaus issued a price target of $40.00 for CELC on 2024-05-30 14:29:00. The adjusted price target was set to $40.00. At the time of the announcement, CELC was trading at $15.28. The overall price target consensus is at ...